NCT05966025View on ClinicalTrials.gov

Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Fatty Liver DiseaseFatty Liver
Interventions
DRUG

Itopride

itopride will be taken by pateints one time per day by dose 100 mg

DRUG

conventional therapy

will taken by patient in control group

Trial Locations (1)

12573

Maha Youssif Fekry, Giza

All Listed Sponsors
collaborator

Beni-Suef University

OTHER

lead

October 6 University

OTHER